Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Asset Writedowns and Impairment (2019 - 2026)

Akebia Therapeutics has reported Asset Writedowns and Impairment over the past 7 years, most recently at $1.9 million for Q4 2025.

  • Quarterly Asset Writedowns and Impairment rose 188.19% to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, up 15833.33% year-over-year, with the annual reading at $2.5 million for FY2025, 752.04% up from the prior year.
  • Asset Writedowns and Impairment was $1.9 million for Q4 2025 at Akebia Therapeutics, up from $500000.0 in the prior quarter.
  • Over five years, Asset Writedowns and Impairment peaked at $7.9 million in Q4 2021 and troughed at -$9.6 million in Q4 2022.
  • The 5-year median for Asset Writedowns and Impairment is $700000.0 (2023), against an average of $1.1 million.
  • Year-over-year, Asset Writedowns and Impairment soared 3551.08% in 2021 and then crashed 221.12% in 2022.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $7.9 million in 2021, then crashed by 221.12% to -$9.6 million in 2022, then soared by 107.29% to $700000.0 in 2023, then crashed by 401.29% to -$2.1 million in 2024, then surged by 188.19% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Asset Writedowns and Impairment are $1.9 million (Q4 2025), $500000.0 (Q3 2025), and -$2.1 million (Q4 2024).